New Drugs Not Improving Upon Generics Should Not Be Reimbursed – Pfizer
Executive Summary
New drugs that are not shown to be better than existing generic agents should not receive reimbursement, Pfizer Senior VP-Science & Technology Peter Corr suggested May 16